Spectrum™ Pre-implantation Genetic Testing
Genetic abnormalities, including aneuploidies, monosomies, structural rearrangements, and pathogenic variants, are major causes of implantation failure, miscarriage, congenital anomalies, and poor outcomes in assisted reproductive technology (ART). Less than 31% of embryos implanted after in vitro fertilization (IVF) survive to live birth.
Pre-implantation genetic testing (PGT) improves reproductive outcomes by identifying embryos free of chromosomal abnormalities or disease-causing variants prior to transfer. Spectrum™ PGT provides three types of testing:
- PGT-A: Detects numerical chromosomal abnormalities (aneuploidy, gain, or loss).
- PGT-SR: Identifies structural rearrangements, including translocations and inversions.
- PGT-M: Screens for specific single-gene mutations and pathogenic variants.
The process involves trophectoderm biopsy, single cell isolation, DNA amplification, and molecular karyotyping by DNA microarray. Unlike conventional embryo karyotyping, microarray technology can also detect balanced chromosomal rearrangements often missed by standard cytogenetics.
- Detects chromosomal abnormalities implicated in miscarriage and genetic disease
- Facilitates selection of the highest-quality, genetically unaffected embryos for implantation
- Increases IVF success rates and live birth outcomes
- Reduces miscarriage risk and improves the likelihood of a healthy child
Embryos categorized as Low Risk are considered the most suitable for transfer.
Fertilized embryo biopsy: cells from trophectoderm, Parental blood samples or buccal swabs may be required for PGT-M.
Stability
Samples should be handled per Spectrum™ kit instructions.
- Hum Reprod. 2010 Apr;25(4):1066-75. [PMID: 20100701]
- Hum Reprod. 2013 Feb;28(2):509-18. [PMID: 23148203]
- Hum Reprod Update. 2019 Jan 1;25(1):15-33. [PMID: 30395265]
- Reprod Biol Endocrinol. 2014 Nov 24;12:105. [PMID: 25420429]